GSK: agreement with China's Zhifei to promote Shingrix
(CercleFinance.com) - GSK today announced that it has entered into an exclusive agreement with Chongqing Zhifei Biological Products (Zhifei) to co-promote GSK's shingles vaccine, Shingrix, in China for an initial period of three years, with the possibility of extending the partnership if all parties agree.
Zhifei, which is China's largest vaccine company in terms of sales, has a proven track record in promoting access to innovative vaccines in China.
From 1 January 2024, Zhifei will enjoy exclusive import and distribution rights for Shingrix in China, focusing on promoting the vaccine through its extensive service network, which covers over 30,000 vaccination points across the country.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Zhifei, which is China's largest vaccine company in terms of sales, has a proven track record in promoting access to innovative vaccines in China.
From 1 January 2024, Zhifei will enjoy exclusive import and distribution rights for Shingrix in China, focusing on promoting the vaccine through its extensive service network, which covers over 30,000 vaccination points across the country.
Copyright (c) 2023 CercleFinance.com. All rights reserved.